Ozurdex dexamethasone intravitreal implant regulatory update

Allergan submitted an sNDA to FDA and a Type II variation application to EMA seeking to expand the label of Ozurdex dexamethasone intravitreal implant to include diabetic macular edema. The biodegrada...